Last reviewed · How we verify
Alcohol N-acetylcysteine
At a glance
| Generic name | Alcohol N-acetylcysteine |
|---|---|
| Also known as | NAC |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) (PHASE4)
- Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients (PHASE2, PHASE3)
- Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease (PHASE2)
- Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD) (PHASE2)
- N-Acetylcysteine for Adolescent Alcohol Use Disorder (PHASE2)
- Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alcohol N-acetylcysteine CI brief — competitive landscape report
- Alcohol N-acetylcysteine updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI